Cros

Trialbee and Acclinate Partner to Enhance Equitable Clinical Trial Participation

Retrieved on: 
Tuesday, December 13, 2022

The partnership is aimed at achieving greater equity in clinical trial participation by leveraging the NOWINCLUDED community through Trialbee Honey Omnichannel.

Key Points: 
  • The partnership is aimed at achieving greater equity in clinical trial participation by leveraging the NOWINCLUDED community through Trialbee Honey Omnichannel.
  • Trialbee will work with Acclinate to access and engage communities of color, encouraging disease and trial awareness within designated geographies.
  • Racial and ethnic minorities comprise 42% of the U.S. population but only account for 2% to 16% of clinical trial participants.
  • We are a digital health company specializing in accessing and engaging communities of color so they can make informed decisions about clinical trial participation.

Everest Group Names Medidata a ‘Leader’ and ‘Star Performer’ in Decentralized Clinical Trial Platforms

Retrieved on: 
Tuesday, December 13, 2022

Medidata , a Dassault Systmes company, has been named a Leader and Star Performer in the Decentralized Clinical Trial Platforms PEAK Matrix Assessment 2023 by Everest Group.

Key Points: 
  • Medidata , a Dassault Systmes company, has been named a Leader and Star Performer in the Decentralized Clinical Trial Platforms PEAK Matrix Assessment 2023 by Everest Group.
  • The annual report evaluates decentralized clinical trial (DCT) products from 24 companies based on vision, capability, and market impact.
  • Its solution is highly recognized for governance, security, and compliance by clients, said Chunky Satija, vice president at Everest Group.
  • Recognition from Everest as both a Leader and Star Performer validates the success we have gained with our sponsors and CROs.

The Worldwide Single-use Assemblies Industry is Expected to Reach $39 Billion by 2030 - ResearchAndMarkets.com

Retrieved on: 
Monday, December 12, 2022

As pharmaceutical companies, distributors, CDMOs, and manufacturers converge around the benefits of single-use assemblies, the industry will grow at a faster pace during the forecast period.

Key Points: 
  • As pharmaceutical companies, distributors, CDMOs, and manufacturers converge around the benefits of single-use assemblies, the industry will grow at a faster pace during the forecast period.
  • From therapies for rare diseases to cancer research, the impact of single-use technology in accelerating cutting-edge research into these conditions is set to grow, thereby propelling industry growth.
  • Single-use assemblies support manufacturers in overcoming this difficulty by eliminating or reducing the necessity for sterilization between the batches, thereby filtering the operational capability.
  • Owing to such advantages, the adoption of single-use assemblies is increasing, thereby driving industry growth.

China Cell Therapy Market Opportunity & Clinical Trials Report 2022-2028: Insight on More Than 400 Cell Therapies in Clinical Trials by Phase, Indication, Company - ResearchAndMarkets.com

Retrieved on: 
Friday, December 9, 2022

The "China Cell Therapy Market Opportunity & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "China Cell Therapy Market Opportunity & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering.
  • Chinese pharmaceutical companies have moved their focus from manufacturing generic drugs to developing innovative drugs and therapies after learning from their international counterparts.
  • CAR T Cell therapy is one of the most popular immunotherapies in China.
  • Insight On More Than 400 Cell Therapies In Clinical Trials By Phase, Indication, Company

RegASK announces US$10m Series A Funding Round led by Monograph Capital to accelerate its growth

Retrieved on: 
Thursday, December 15, 2022

SINGAPORE, Dec. 15, 2022 /PRNewswire/ -- RegASK,a global RegTech SaaS company, today announced it has raised a $10m Series A funding round.

Key Points: 
  • SINGAPORE, Dec. 15, 2022 /PRNewswire/ -- RegASK,a global RegTech SaaS company, today announced it has raised a $10m Series A funding round.
  • The round is led by venture capital firm Monograph Capital and joined by SPRIM Global Investments and other investors.
  • The funding will be used to further invest in the platform and bring RegASK to all companies seeking to strengthen their regulatory capabilities around the globe.
  • "The addition of Monograph Capital is strategic to RegASK's development roadmap" said Caroline Shleifer, PhD, CEO of RegASK.

Avirmax CMC Inc. Successfully Manufactured and Delivered to a Client the First Lot of rAAV Drug Product for a Monkey Toxicology Study

Retrieved on: 
Thursday, December 15, 2022

The manufacturing process was conducted in ACI's cGMP facility, recently licensed by California Department of Public Health (CDPH)-Food & Drug Branch, for the production of rAAV drug products for use in clinical investigations.

Key Points: 
  • The manufacturing process was conducted in ACI's cGMP facility, recently licensed by California Department of Public Health (CDPH)-Food & Drug Branch, for the production of rAAV drug products for use in clinical investigations.
  • Release testing of the rAAV product were performed in-house and by selected contract research organizations (CROs) in the U.S., thus speeding up the product release process.
  • The manufacturing platform contains orthogonal virus clearance technologies to ensure product virological safety.
  • It offers its clients with great transparency and flexible services with solid process development expertise, skills and knowledge in rAAV manufacturing, testing and quality management.

Biologics Contract Development Global Market Report 2022: Advanced Technologies for Biological Production Boost Sector Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 7, 2022

The Biologics Contract Development Market size is expected to reach USD 13.22 billion by 2030, according to a new study.

Key Points: 
  • The Biologics Contract Development Market size is expected to reach USD 13.22 billion by 2030, according to a new study.
  • The report gives a detailed insight into current market dynamics and provides an analysis of future market growth.
  • The market is being driven by factors such growing use of advanced technologies for biological production, increased R&D activities by pharmaceutical and biopharma businesses, and supportive regulations for clinical trials in developing nations.
  • The publisher has segmented the biologics contract development market report based on source, product service, indication, and region:
    Biologics Contract Development, Source Outlook (Revenue - USD Billion, 2018 - 2030)

Recombinant Proteins Market Report 2022: Increasing Government Investments and Rising Focus on Personalized Medicine to Drive Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 6, 2022

Based on end users, the recombinant proteins market is segmented into pharmaceutical & biopharmaceutical companies, biotechnology companies, academic research institutes, contract research organizations, and other end users.

Key Points: 
  • Based on end users, the recombinant proteins market is segmented into pharmaceutical & biopharmaceutical companies, biotechnology companies, academic research institutes, contract research organizations, and other end users.
  • The vaccine segment will witness the second-highest growth in the recombinant proteins market during the forecast period.
  • Geographically, the recombinant proteins market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa.
  • In 2021, North America accounted for the largest share of the recombinant proteins market.

Rare Disease Genetic Testing Market Report 2022: Advancements Such as NGS and Microarray Testing Drive Sector - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 6, 2022

The "Rare Disease Genetic Testing Market Share, Size, Trends, Industry Analysis Report, By Specialty; By Technology; By Disease Type; By End-Use; By Region; Segment Forecast, 2022-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Rare Disease Genetic Testing Market Share, Size, Trends, Industry Analysis Report, By Specialty; By Technology; By Disease Type; By End-Use; By Region; Segment Forecast, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global rare disease genetic testing market size is expected to reach USD 2,414.90 million by 2030 according to a new study.
  • The report gives a detailed insight into current market dynamics and provides analysis on future market growth.
  • The publisher has segmented the rare disease genetic testing market report based on disease type, technology, specialty, end-use, and regions:
    Rare Disease Genetic Testing, Disease Type Outlook (Revenue - USD Million, 2018 - 2030)

Medidata Launches New myMedidata Native App to Expedite Study Start Up and Improve Patient Experience

Retrieved on: 
Tuesday, December 6, 2022

The app will feature all of the myMedidata patient-centric solutions, with an initial focus on eCOA (electronic clinical outcome assessments).

Key Points: 
  • The app will feature all of the myMedidata patient-centric solutions, with an initial focus on eCOA (electronic clinical outcome assessments).
  • Medidata is leveraging its unique insights from sponsors, CROs, sites, and patients to make a meaningful difference in the clinical trial experience.
  • The app is configured using Medidata Designer, a new platform configuration tool, bringing a patient-centered mobile-first workflow builder to the myMedidata app.
  • Designer drastically lowers study build times by employing Medidata and client libraries, including pre-built eCOA instruments, translations, and study configurations.